학술논문
P-052: Measurable residual disease (MRD) dynamics during maintenance with ixazomib vs placebo in 1280 newly diagnosed multiple myeloma (NDMM) patients: a pooled analysis of the TOURMALINE-MM3 and -MM4 trials
Document Type
Abstract
Author
Paiva, Bruno; Manrique, Irene; Dimopoulos, Meletios A.; Gay, Francesca; Min, Chang-Ki; Zweegman, Sonja; Špička, Ivan; Teipel, Raphael; Mateos, María-Victoria; Giuliani, Nicola; Cavo, Michele; Hopkins, Christine Rojas; Fun, Weijun; Suryanarayan, Kaveri; Vorog, Alexander; Li, Cong; Wang, Bingxia; Estevam, Jose; Labotka, Richard; Dash, Ajeeta
Source
In Clinical Lymphoma, Myeloma and Leukemia August 2022 22 Supplement:S63-S64
Subject
Language
ISSN
2152-2650